Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence

the Sentinel Node and Recurrent Breast Cancer (SNARB) study group; I. G.M. Poodt; G. Vugts; R. J. Schipper; R. M.H. Roumen; H. J.T. Rutten; A. J.G. Maaskant-Braat; A. C. Voogd; G. A.P. Nieuwenhuijzen

doi:10.1002/bjs.11097

Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence

the Sentinel Node and Recurrent Breast Cancer (SNARB) study group, I. G.M. Poodt^*, G. Vugts, R. J. Schipper, R. M.H. Roumen, H. J.T. Rutten, A. J.G. Maaskant-Braat, A. C. Voogd, G. A.P. Nieuwenhuijzen

^*Corresponding author voor dit werk

Onderzoeksoutput › Academic › peer review

10 Citaten (Scopus)

1 Downloads (Pure)

Samenvatting

Background:
Ipsilateral breast tumour recurrence (IBTR) has an unfavourable prognosis, with a significant subsequent risk of distant recurrence. Repeat sentinel lymph node biopsy (rSLNB) has recently been demonstrated to be technically feasible and useful in tailoring adjuvant treatment plans in patients with IBTR. The prognostic impact of rSLNB in patients with IBTR remains unclear. This study analysed the risk of distant recurrence after IBTR, and evaluated the prognostic impact of rSLNB and other patient and tumour characteristics on distant recurrence-free survival.

Methods:
Data were obtained from the SNARB (Sentinel Node and Recurrent Breast Cancer) study. Cox proportional hazards analyses were performed to assess the prognostic effect of tumour, patient and treatment factors on distant recurrence-free survival.

Results:
Of the 515 included patients, 230 (44·7 per cent) had a tumour-negative rSLNB and 46 (8·9 per cent) a tumour-positive rSLNB. In 239 patients (46·4 per cent) the rSLNB procedure was unsuccessful. After a median follow-up of 5·1 years, 115 patients (22·3 per cent) had developed a recurrence. The overall 5-year distant recurrence-free survival rate was 84·2 (95 per cent c.i. 80·7 to 87·7) per cent. An interval of less than 2 years between primary breast cancer treatment and ipsilateral recurrence (P = 0·018), triple-negative IBTR (P = 0·045) and absence of adjuvant chemotherapy after IBTR (P = 0·010) were independently associated with poor distant recurrence-free survival. The association between the outcome of rSLNB and distant recurrence-free survival was not statistically significant (P = 0·682).

Conclusion:
The outcome of rSLNB is not an important prognostic factor for distant recurrence, and its value as a staging tool in patients with IBTR seems disputable.

Originele taal-2	English
Pagina's (van-tot)	574-585
Aantal pagina's	12
Tijdschrift	British Journal of Surgery
Volume	106
Nummer van het tijdschrift	5
DOI's	https://doi.org/10.1002/bjs.11097
Status	Published - apr.-2019

Toegang tot document

10.1002/bjs.11097

Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrenceFinal publisher's version, 370 KBLicentie: Taverne

Handle.net

Permanente koppeling

Andere bestanden en links

Link naar publicatie in Scopus

Citeer dit

the Sentinel Node and Recurrent Breast Cancer (SNARB) study group, Poodt, I. G. M., Vugts, G., Schipper, R. J., Roumen, R. M. H., Rutten, H. J. T., Maaskant-Braat, A. J. G., Voogd, A. C., & Nieuwenhuijzen, G. A. P. (2019). Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. British Journal of Surgery, 106(5), 574-585. https://doi.org/10.1002/bjs.11097

@article{de87ca920e9c4181b762f303c6f1579a,

title = "Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence",

abstract = "Background: Ipsilateral breast tumour recurrence (IBTR) has an unfavourable prognosis, with a significant subsequent risk of distant recurrence. Repeat sentinel lymph node biopsy (rSLNB) has recently been demonstrated to be technically feasible and useful in tailoring adjuvant treatment plans in patients with IBTR. The prognostic impact of rSLNB in patients with IBTR remains unclear. This study analysed the risk of distant recurrence after IBTR, and evaluated the prognostic impact of rSLNB and other patient and tumour characteristics on distant recurrence-free survival. Methods: Data were obtained from the SNARB (Sentinel Node and Recurrent Breast Cancer) study. Cox proportional hazards analyses were performed to assess the prognostic effect of tumour, patient and treatment factors on distant recurrence-free survival. Results: Of the 515 included patients, 230 (44·7 per cent) had a tumour-negative rSLNB and 46 (8·9 per cent) a tumour-positive rSLNB. In 239 patients (46·4 per cent) the rSLNB procedure was unsuccessful. After a median follow-up of 5·1 years, 115 patients (22·3 per cent) had developed a recurrence. The overall 5-year distant recurrence-free survival rate was 84·2 (95 per cent c.i. 80·7 to 87·7) per cent. An interval of less than 2 years between primary breast cancer treatment and ipsilateral recurrence (P = 0·018), triple-negative IBTR (P = 0·045) and absence of adjuvant chemotherapy after IBTR (P = 0·010) were independently associated with poor distant recurrence-free survival. The association between the outcome of rSLNB and distant recurrence-free survival was not statistically significant (P = 0·682). Conclusion: The outcome of rSLNB is not an important prognostic factor for distant recurrence, and its value as a staging tool in patients with IBTR seems disputable.",

author = "{the Sentinel Node and Recurrent Breast Cancer (SNARB) study group} and Poodt, {I. G.M.} and G. Vugts and Schipper, {R. J.} and Roumen, {R. M.H.} and Rutten, {H. J.T.} and Maaskant-Braat, {A. J.G.} and Voogd, {A. C.} and Nieuwenhuijzen, {G. A.P.} and Luiten, {E. J.T.} and Rutgers, {E. J.T.} and Vrancken-Peeters, {M. T.F.D.} and M. Bessems and Klaase, {J. M.} and S. Muller and Francken, {A. B.} and {Van Dalen}, T. and L. Jansen and Koopal, {S. A.} and Vissers, {Y. L.J.} and Smidt, {M. L.} and Merkus, {J. W.S.} and Contant, {C. M.E.} and Veldman, {P. H.} and Linthorst-Niers, {E. M.H.} and {van der Sijp}, {J. R.} and Guicherit, {O. R.} and Koppert, {L. B.} and Bosch, {A. M.} and Strobbe, {L. J.A.} and Schlooz-Vries, {M. S.} and Arntz, {I. E.} and {van Essen}, {J. A.} and {de Waard}, {J. W.D.} and Vrouenraets, {B. C.} and {van Ooijen}, B.",

note = "Publisher Copyright: {\textcopyright} 2019 BJS Society Ltd Published by John Wiley & Sons Ltd",

year = "2019",

month = apr,

doi = "10.1002/bjs.11097",

language = "English",

volume = "106",

pages = "574--585",

journal = "British Journal of Surgery",

issn = "0007-1323",

publisher = "Wiley",

number = "5",

}

the Sentinel Node and Recurrent Breast Cancer (SNARB) study group, Poodt, IGM, Vugts, G, Schipper, RJ, Roumen, RMH, Rutten, HJT, Maaskant-Braat, AJG, Voogd, AC & Nieuwenhuijzen, GAP 2019, 'Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence', British Journal of Surgery, vol. 106, nr. 5, blz. 574-585. https://doi.org/10.1002/bjs.11097

TY - JOUR

T1 - Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence

AU - the Sentinel Node and Recurrent Breast Cancer (SNARB) study group

AU - Poodt, I. G.M.

AU - Vugts, G.

AU - Schipper, R. J.

AU - Roumen, R. M.H.

AU - Rutten, H. J.T.

AU - Maaskant-Braat, A. J.G.

AU - Voogd, A. C.

AU - Nieuwenhuijzen, G. A.P.

AU - Luiten, E. J.T.

AU - Rutgers, E. J.T.

AU - Vrancken-Peeters, M. T.F.D.

AU - Bessems, M.

AU - Klaase, J. M.

AU - Muller, S.

AU - Francken, A. B.

AU - Van Dalen, T.

AU - Jansen, L.

AU - Koopal, S. A.

AU - Vissers, Y. L.J.

AU - Smidt, M. L.

AU - Merkus, J. W.S.

AU - Contant, C. M.E.

AU - Veldman, P. H.

AU - Linthorst-Niers, E. M.H.

AU - van der Sijp, J. R.

AU - Guicherit, O. R.

AU - Koppert, L. B.

AU - Bosch, A. M.

AU - Strobbe, L. J.A.

AU - Schlooz-Vries, M. S.

AU - Arntz, I. E.

AU - van Essen, J. A.

AU - de Waard, J. W.D.

AU - Vrouenraets, B. C.

AU - van Ooijen, B.

PY - 2019/4

Y1 - 2019/4

N2 - Background: Ipsilateral breast tumour recurrence (IBTR) has an unfavourable prognosis, with a significant subsequent risk of distant recurrence. Repeat sentinel lymph node biopsy (rSLNB) has recently been demonstrated to be technically feasible and useful in tailoring adjuvant treatment plans in patients with IBTR. The prognostic impact of rSLNB in patients with IBTR remains unclear. This study analysed the risk of distant recurrence after IBTR, and evaluated the prognostic impact of rSLNB and other patient and tumour characteristics on distant recurrence-free survival. Methods: Data were obtained from the SNARB (Sentinel Node and Recurrent Breast Cancer) study. Cox proportional hazards analyses were performed to assess the prognostic effect of tumour, patient and treatment factors on distant recurrence-free survival. Results: Of the 515 included patients, 230 (44·7 per cent) had a tumour-negative rSLNB and 46 (8·9 per cent) a tumour-positive rSLNB. In 239 patients (46·4 per cent) the rSLNB procedure was unsuccessful. After a median follow-up of 5·1 years, 115 patients (22·3 per cent) had developed a recurrence. The overall 5-year distant recurrence-free survival rate was 84·2 (95 per cent c.i. 80·7 to 87·7) per cent. An interval of less than 2 years between primary breast cancer treatment and ipsilateral recurrence (P = 0·018), triple-negative IBTR (P = 0·045) and absence of adjuvant chemotherapy after IBTR (P = 0·010) were independently associated with poor distant recurrence-free survival. The association between the outcome of rSLNB and distant recurrence-free survival was not statistically significant (P = 0·682). Conclusion: The outcome of rSLNB is not an important prognostic factor for distant recurrence, and its value as a staging tool in patients with IBTR seems disputable.

AB - Background: Ipsilateral breast tumour recurrence (IBTR) has an unfavourable prognosis, with a significant subsequent risk of distant recurrence. Repeat sentinel lymph node biopsy (rSLNB) has recently been demonstrated to be technically feasible and useful in tailoring adjuvant treatment plans in patients with IBTR. The prognostic impact of rSLNB in patients with IBTR remains unclear. This study analysed the risk of distant recurrence after IBTR, and evaluated the prognostic impact of rSLNB and other patient and tumour characteristics on distant recurrence-free survival. Methods: Data were obtained from the SNARB (Sentinel Node and Recurrent Breast Cancer) study. Cox proportional hazards analyses were performed to assess the prognostic effect of tumour, patient and treatment factors on distant recurrence-free survival. Results: Of the 515 included patients, 230 (44·7 per cent) had a tumour-negative rSLNB and 46 (8·9 per cent) a tumour-positive rSLNB. In 239 patients (46·4 per cent) the rSLNB procedure was unsuccessful. After a median follow-up of 5·1 years, 115 patients (22·3 per cent) had developed a recurrence. The overall 5-year distant recurrence-free survival rate was 84·2 (95 per cent c.i. 80·7 to 87·7) per cent. An interval of less than 2 years between primary breast cancer treatment and ipsilateral recurrence (P = 0·018), triple-negative IBTR (P = 0·045) and absence of adjuvant chemotherapy after IBTR (P = 0·010) were independently associated with poor distant recurrence-free survival. The association between the outcome of rSLNB and distant recurrence-free survival was not statistically significant (P = 0·682). Conclusion: The outcome of rSLNB is not an important prognostic factor for distant recurrence, and its value as a staging tool in patients with IBTR seems disputable.

UR - http://www.scopus.com/inward/record.url?scp=85063430288&partnerID=8YFLogxK

U2 - 10.1002/bjs.11097

DO - 10.1002/bjs.11097

M3 - Article

C2 - 30908615

AN - SCOPUS:85063430288

SN - 0007-1323

VL - 106

SP - 574

EP - 585

JO - British Journal of Surgery

JF - British Journal of Surgery

IS - 5

ER -

Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence

Samenvatting

Toegang tot document

Handle.net

Andere bestanden en links

Vingerafdruk

Citeer dit